awmsg logo



misoprostol (Mysodelle®)


Reference No. 2041

Publication date:
05/08/2016


Last review date:
05/08/2019

Appraisal information

misoprostol (Mysodelle®) 200 micrograms vaginal delivery system


Company: Ferring Pharmaceuticals (UK)
BNF category: Obstetrics, gynaecology, and urinary-tract disorders
NMG meeting date: 11/05/2016
AWMSG meeting date: 15/06/2016
   
   
Submission Type: Full Submission
Status: Not recommended
Advice No: 1416
Ministerial ratification: 05/08/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Misoprostol (Mysodelle®) is not recommended for use within NHS Wales for the induction of labour in women with an unfavourable cervix, from 36 weeks gestation, in whom induction is clinically indicated. The case for cost-effectiveness has not been proven.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download